目的:评价多索茶碱联合哌拉西林他唑吧坦对急性加重期慢性阻塞性肺疾病(Acute Exacerbation of Chronic Obstructive Pulmonary Disease,AECOPD)伴肺炎患者的治疗效果,以及对细菌清除率、血气指标和临床预后的影响.方法:纳入66名于2021 年1月到2024 年3月间诊断为 AECOPD伴肺炎患者.随机分为两组,对照组(n=33)接受哌拉西林他唑吧坦治疗,观察组(n=33)在对照组基础上加用多索茶碱治疗.治疗周期7 d.治疗前后,比较患者氧分压(Partial Pressure of Oxygen,PaO2)、二氧化碳分压(Partial Pressure of Carbon Dioxide,PaCO2)、血pH值、剩余碱(Base Excess,BE)以及碳酸氢根离子浓度(HCO3-);记录临床症状缓解情况,统计细菌清除率;监测不良反应.结果:治疗后,观察组体内细菌清除率显著高于对照组(P＜0.05);观察组较对照组血浆PaO2,pH,BE,HCO3-明显增高,PaCO2显著降低(P＜0.05);观察组患者临床症状积分较对照组明显降低(P＜0.05).且两组间的毒副作用无统计学意义(P＞0.05).结论:多索茶碱联合哌拉西林他唑吧坦治疗AECOPD伴肺炎患者,能有效提高细菌清除率,改善血气指标,改善临床预后,且安全性良好.
Influence of doxofylline combined with piperacillin-tazobactam on bacterial clearance rate,blood gas indicators and prognosis in patients with AECOPD complicated with pneumonia
Objective:To evaluate the therapeutic effect of doxofylline combined with piperacillin-tazobactam on patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)complicated with pneumonia and its influence on bacterial clearance rate,blood gas indicators and clinical prognosis.Methods:A total of 66 patients who were diagnosed as AECOPD with pneumonia from January 2021 to March 2024 were included and randomly divided into two groups.The control group(n=33)was treated with piperacillin-tazobactam,while the observation group(n=33)was added with doxofylline on the basis of the control group.The treatment cycle was 7 days.Partial pressure of oxygen(PaO2),partial pressure of carbon dioxide(PaCO2),blood pH value,base excess(BE)and bicarbonate ion concentration(HCO3-)were compared before and after treatment.The clinical symptom relief was recorded,and the bacterial clearance rate was counted,and adverse reactions were monitored.Results:After treatment,the bacterial clearance rate in observation group was significantly higher than that in control group(P<0.05).Compared with the control group,the PaO2,pH,BE and HCO3-in observation group were significantly higher while PaCO2 was significantly lower(P<0.05).The clinical symptoms scores in observation group were significantly reduced than those in control group(P<0.05).There were no statistical differences in toxic and side effects between groups(P>0.05).Conclusion:Doxofylline combined with piperacillin-tazobactam can effectively enhance the bacterial clearance rate,improve the blood gas indicators,and promote the clinical prognosis in the treatment of AECOPD patients with pneumonia,and it has good safety.
DoxofyllinePiperacillin-tazobactamAcute exacerbation of chronic obstructive pulmonary diseaseBacterial clearance rate
NETL
NSTL
万方数据
